BLUW - SPAC Blue Water Acquisition taking Clarus Therapeutics public

Special purpose acquisition company ("SPAC") Blue Water Acquisition Corp. (BLUW) will merge with Clarus Therapeutics resulting in Clarus becoming a publicly trading company.Clarus is expected to trade on Nasdaq.The deal values Clarus at $379M and is expected to close in Q3 2021.Existing Clarus stakeholders will invest another $25M into the company.Clarus' sole product is Jatenzo, an oral testosterone replacement therapy.Blue Water is up 0.1% to $10.11 in afternoon trading.

For further details see:

SPAC Blue Water Acquisition taking Clarus Therapeutics public